Search for Clinical Trial Results

Sponsored By

Pyoderma Gangrenosum - 13 Studies Found

Status Study
Completed Study Name: A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2013-10-15
Interventions: Biological: Xilonix IV
Terminated Study Name: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2014-12-08
Interventions: Drug: gevokizumab
Terminated Study Name: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2014-12-22
Interventions:
  • Drug: gevokizumab
  • Drug: Placebo
Completed Study Name: Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2013-06-17
Interventions: Drug: gevokizumab
Completed Study Name: Canakinumab for Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2011-02-17
Interventions: Drug: Canakinumab Monoclonal antibody inhibiting interleukin 1 beta
Recruiting Study Name: An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2017-04-27
Interventions: Biological: Ixekizumab Injection Other Name: Taltz
Withdrawn Study Name: Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2008-08-04
Interventions:
  • Drug: Humira Will receive 80 m
Not yet recruiting Study Name: Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2017-02-17
Interventions: Drug: APD334 Other Name: Etrasimod
Recruiting Study Name: Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2016-03-28
Interventions: Drug: Secukinumab
Withdrawn Study Name: Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2008-06-02
Interventions: Drug: adalimumab 40 mg weekly adalimumab injection.
Next >>>